180 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Kris
    Kris
  4. Hyman
    Hyman
  5. Arcila
    Arcila
  6. Li
    Li
  7. Riely
    Riely
  8. Rudin
    Rudin
  9. Offin
    Offin
  10. Schram
    Schram

Groups

  1. Department of Medicine (180)
  2. Solid Tumor Oncology Division (180)
  3. Thoracic Oncology (180)
  4. GSK Faculty (79)
  5. Human Oncology and Pathogenesis Program (67)
  6. Tow Center for Developmental Oncology (TCDO) (57)
  7. Early Drug Development Service (44)
  8. Sloan Kettering Institute Postdocs (44)
  9. Radiology, Department of (38)
  10. Epidemiology and Biostatistics (36)
  1. "Solid Tumor Oncology Division"
  2. "Journal article"
  3. "Alexander Drilon"
  4. "Thoracic Oncology"
Formats
  1. Journal Article (180)
Groups
  1. Department of Medicine (180)
  2. Solid Tumor Oncology Division (180)
  3. Thoracic Oncology (180)
  4. GSK Faculty (79)
  5. Human Oncology and Pathogenesis Program (67)
  6. Tow Center for Developmental Oncology (TCDO) (57)

More Groups

People
  1. Alexander Drilon (180)
  2. Marc Ladanyi (53)
  3. Maria Arcila (36)
  4. Mark Kris (36)
  5. David Hyman (31)
  6. Bob Li (29)

More People

Years
  1. 2023 (11)
  2. 2022 (30)
  3. 2021 (28)
  4. 2020 (21)
  5. 2019 (23)
  6. 2018 (22)

More Years

Publications
  1. Clinical Cancer Research (25)
  2. JCO Precision Oncology (16)
  3. Journal of Thoracic Oncology (15)
  4. Cancer Discovery (12)
  5. Annals of Oncology (11)
  6. Journal of Clinical Oncology (8)

More Publications

Publishers
  1. American Association for Cancer Research (40)
  2. Elsevier Inc. (26)
  3. American Society of Clinical Oncology (25)
  4. Oxford University Press (15)
  5. Nature Publishing Group (14)
  6. Elsevier Science, Inc. (8)

More Publishers

Results (180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy
    Journal Article

    Drilon, A.; Sharma, M. R.; Johnson, M. L.; Yap, T. A.; Gadgeel, S.; Nepert, D.; Feng, G.; Reddy, M. B.; Harney, A. S.; Elsayed, M.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Mitogen-activated pathway kinase (MAPK) inhibitor-associated retinopathy: Do features differ with upstream versus down-stream inhibition?
    Journal Article

    Francis, J. H.; Foulsham, W.; Canestraro, J.; Harding, J. J.; Diamond, E. L.; Drilon, A.; Abramson, D. H.
    Ocular Oncology and Pathology (2023)

    Fulltext@MSK | Save
  • A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
    Journal Article

    Repetto, M.; Crimini, E.; Belli, C.; Boscolo Bielo, L.; Ascione, L.; Meric-Bernstam, F.; Drilon, A.; Curigliano, G.
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
    Journal Article

    Goldman, J. W.; Sholl, L. M.; Dacic, S.; Fishbein, M. C.; Murciano-Goroff, Y. R.; Rajaram, R.; Szymczak, S.; Szpurka, A. M.; Chao, B. H.; Drilon, A.
    Frontiers in Oncology (2023)

    Fulltext@MSK | Save
  • Central nervous system disease in patients with RET fusion-positive NSCLC treated with selpercatinib
    Journal Article

    Murciano-Goroff, Y. R.; Falcon, C. J.; Lin, S. T.; Chacko, C.; Grimaldi, G.; Liu, D.; Wilhelm, C.; Iasonos, A.; Drilon, A.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics
    Journal Article

    Polk, J. B.; Campbell, J.; Drilon, A. E.; Keating, P.; Cambrosio, A.
    Social Science and Medicine (2023)

    Fulltext@MSK | Save
  • NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations
    Journal Article

    Drilon, A.; Horan, J. C.; Tangpeerachaikul, A.; Besse, B.; Ou, S. H. I.; Gadgeel, S. M.; Camidge, D. R.; van der Wekken, A. J.; Nguyen-Phuong, L.; Acker, A.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Characterization of central nervous system clinico-genomic outcomes in ALK-positive non-small cell lung cancer patients with brain metastases treated with alectinib
    Journal Article

    Miao, E.; Eichholz, J. E.; Lebow, E. S.; Flynn, J.; Zhang, Z.; Walch, H.; Hubbeling, H.; Beal, K.; Moss, N. S.; Yu, K. K.; more...
    Lung Cancer (2023)

    Fulltext@MSK | Save
  • Selpercatinib in patients with RET fusion–positive non–small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial
    Journal Article

    Drilon, A.; Subbiah, V.; Gautschi, O.; Tomasini, P.; de Braud, F.; Solomon, B. J.; Shao-Weng Tan, D.; Alonso, G.; Wolf, J.; Park, K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save